2 weeks Ago By ABMN Staff
American Century Companies Inc. increased its position in shares of Innoviva, Inc. ( NASDAQ:INVA – Free Report ) by 35.
2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,424,315 shares of the biotechnology company’s stock after buying an additional 370,795 shares during the period. American Century Companies Inc.
owned 2.28% of Innoviva worth $24,712,000 at the end of the most recent reporting period. Other large investors have also modified their holdings of the company.
Boston Partners lifted its position in Innoviva by 43.7% during the 4th quarter. Boston Partners now owns 490,404 shares of the biotechnology company’s stock worth $8,513,000 after acquiring an additional 149,060 shares during the last quarter.
Pacer Advisors Inc. increased its stake in shares of Innoviva by 4.3% in the fourth quarter.
Pacer Advisors Inc. now owns 2,932,113 shares of the biotechnology company’s stock worth $50,872,000 after purchasing an additional 121,162 shares during the period. Systematic Financial Management LP lifted its position in shares of Innoviva by 4.
7% during the 3rd quarter. Systematic Financial Management LP now owns 1,979,073 shares of the biotechnology company’s stock worth $38,216,000 after purchasing an additional 89,633 shares during the last quarter. Barclays PLC lifted its position in shares of Innoviva by 254.
2% during the 3rd quarter. Barclays PLC now owns 100,594 shares of the biotechnology company’s stock worth $1,942,000 after purchasing an additional 72,192 shares during the last quarter. Finally, JPMorgan Chase & Co.
boosted its stake in Innoviva by 14.2% during the 3rd quarter. JPMorgan Chase & Co.
now owns 578,243 shares of the biotechnology company’s stock valued at $11,166,000 after purchasing an additional 72,039 shares during the period. 99.12% of the stock is owned by institutional investors.
Insiders Place Their Bets In related news, major shareholder Alexander J. Denner sold 1,196,746 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $17.
52, for a total value of $20,966,989.92. Following the completion of the transaction, the insider now owns 5,658,705 shares of the company’s stock, valued at $99,140,511.
60. This represents a 17.46 % decrease in their ownership of the stock.
The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink . Corporate insiders own 1.70% of the company’s stock.
Wall Street Analysts Forecast Growth View Our Latest Stock Report on Innoviva Innoviva Stock Up 1.7 % INVA stock opened at $18.18 on Friday.
Innoviva, Inc. has a twelve month low of $14.33 and a twelve month high of $21.
28. The company has a quick ratio of 1.64, a current ratio of 1.
79 and a debt-to-equity ratio of 0.38. The company has a market cap of $1.
14 billion, a PE ratio of 26.35 and a beta of 0.56.
The business’s 50-day simple moving average is $17.99 and its 200 day simple moving average is $18.64.
Innoviva ( NASDAQ:INVA – Get Free Report ) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.57 earnings per share for the quarter.
The company had revenue of $91.81 million for the quarter. Innoviva had a return on equity of 20.
84% and a net margin of 18.31%. On average, research analysts anticipate that Innoviva, Inc.
will post 0.33 earnings per share for the current year. Innoviva Company Profile ( Free Report ) Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally.
The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Featured Articles Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva, Inc.
( NASDAQ:INVA – Free Report ). Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter .
.
